Researchers Able To Identify That Benign Tumors From Use Of Oral Contraceptive Have A Greater Chance Of Becoming Malignant
WASHINGTON, Nov. 3, 2013 /PRNewswire/ -- Although very rare, the use of oral contraceptive can lead to benign tumors in the liver. The tumors, known as hepatocellular adenomas, can become malignant. It is, however, difficult for physicians to assess the risk of these tumors becoming malignant.
The study's researchers examined and classified data from 250 patients with hepatocellular adenomas. They examined classical adenomas (223), borderline lesions between adenomas and carcinomas (18), and carcinomas (9). The data was examined using whole exome sequencing, CGH-SNP analyses, and methylome analyses.
Researchers were able to identify the genetic determinants of malignant transformation as well as the key factors at stages of the transformation. "Our work reported for the first time a molecular mechanism of malignant transformation of hepatocellular adenomas to carcinomas," lead researcher, Camilla Pilati, PhD, said, "Surprisingly, we were able to identify the chronology of the genetic defects that accumulate in hepatocytes to promote their malignant transformation. In this line, we identified genetic alteration that acts at early and late steps of the malignant transformation process, in the accumulation of early genetic alteration at the origin of the malignant transformation of the hepatocytes."
Two genes with somatic mutations -- one in the early stages and one in the later stages -- were identified in the malignant transformation. Mutations of beta-catenin are associated with many forms of cancer, and beta-catenin activation and TERT promoter mutations in the early and later stages, respectively, were identified in the malignancy process. In addition, the researchers were able to identify factors that determined adenomas that were not at a high risk of becoming carcinoma."This work provided new insights about the major genetic determinants of malignant transformation and their timeframe accumulation during the adenoma-carcinoma sequence. At the clinical level, we believe that these results open new avenues for personalized medicine in hepatocellular adenomas," said Dr. Pilati.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts